Thirty-two weeks of pharmacological PARP-1 inhibition by L-2286 treatment attenuated hypertension induced structural and functional alterations of carotid arteries by a lowered level of oxidative damage and an interference with stress related inflammatory and cell death propagating signaling events. The gene discussed is PARP1; the disease is Hypertension.